- Conditions
- Parkinson's Disease
- Interventions
- BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
- Drug
- Lead sponsor
- Bial R&D Investments, S.A.
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 30 more
Location Directory
Clinical trials in Houston, Texas
This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
22526
Shown on this page
12
Current sort
Recently updated
Location scope
Houston, TX
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 637–648 of 22,526 matching trials in Houston, TX.
Live ClinicalTrials.gov results.
Institutions in Houston
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
- Interventions
- Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), Nab-paclitaxel
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more
- Conditions
- Diabetes Mellitus, Overweight, Obesity
- Interventions
- NNC0487-0111, Placebo (matched to NNC0487-0111)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 638 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Escondido, California • Lomita, California + 12 more
- Conditions
- Major Depressive Disorder
- Interventions
- XEN1101, Placebo
- Drug
- Lead sponsor
- James Murrough
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Ulcerative Colitis
- Interventions
- Etrasimod
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 896 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 133
- States / cities
- Dothan, Alabama • Lake Elsinore, California • Lancaster, California + 44 more
- Conditions
- Low Risk Myelodysplastic Syndromes
- Interventions
- R906289 Monosodium (R289 Na)
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 10 more
- Conditions
- Vulvar Cancer
- Interventions
- ICG guided sentinel lymph node biopsy
- Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Tricuspid Regurgitation (TR)
- Interventions
- Tricuspid Transcatheter Edge-to-Edge Repair (TEER)
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 5 more
- Conditions
- Chronic Spinal Cord Injury
- Interventions
- NVG-291, Placebo
- Drug
- Lead sponsor
- NervGen Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Pheonix, Arizona • Downey, California + 18 more
- Conditions
- Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic), Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV, Liver Cancer Stage IV, Liver Cancer Stage IIIa, Liver Cancer Stage IIIb, Liver Cancer Stage IIIc
- Interventions
- EUS-Guided MWA Device
- Device
- Lead sponsor
- Banner Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Gilbert, Arizona • Los Angeles, California • Chicago, Illinois + 3 more
- Conditions
- Myelodysplastic Syndrome, Anemia
- Interventions
- Elritercept, Epoetin Alfa
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 35
- States / cities
- Gilbert, Arizona • Duarte, California • Santa Rosa, California + 30 more
- Conditions
- NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
- Interventions
- Oral MRT-2359
- Drug
- Lead sponsor
- Monte Rosa Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 13 more